CLINICAL TRIALS PROFILE FOR MIGLUSTAT
✉ Email this page to a colleague
All Clinical Trials for MIGLUSTAT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00194649 ↗ | Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2) | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 4 | 2005-06-01 | The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men. We want to see if Miglustat will inhibit sperm production in men and act as a reversible male contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of sperm production. We believe Miglustat may have some potential as a safe, reversible male contraceptive. |
| NCT00194649 ↗ | Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2) | Completed | University of Washington | Phase 4 | 2005-06-01 | The purpose of this research study is to help in the development of safe, effective and reversible male contraception. We are examining the impact of the drug Miglustat on sperm production in normal men. We want to see if Miglustat will inhibit sperm production in men and act as a reversible male contraceptive, as a study in mice administered Miglustat showed a reversible inhibition of sperm production. We believe Miglustat may have some potential as a safe, reversible male contraceptive. |
| NCT00319046 ↗ | Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease | Completed | Actelion | Phase 3 | 2006-02-01 | Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy, safety and tolerability of miglustat in maintaining diseases stability after a switch from ERT. |
| NCT00418847 ↗ | Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis | Completed | Actelion | Phase 2 | 2004-07-01 | The purpose of the study is to investigate the pharmacokinetics of Zavesca (miglustat, OGT918) when given as single and multiple doses in juvenile patients with GM2 gangliosidosis. |
| NCT00418847 ↗ | Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 Gangliosidosis | Completed | The Hospital for Sick Children | Phase 2 | 2004-07-01 | The purpose of the study is to investigate the pharmacokinetics of Zavesca (miglustat, OGT918) when given as single and multiple doses in juvenile patients with GM2 gangliosidosis. |
| NCT00517153 ↗ | Miglustat in Niemann-Pick Type C Disease | Completed | Actelion | Phase 2 | 2002-01-01 | This is a phase II randomized controlled study of miglustat in adult and juvenile patients with Niemann-Pick Type C disease. Up to 42 patients will be randomised in a 2:1 ratio to either treatment with miglustat or to a non-treatment group. Both groups will follow an identical visit schedule. |
| NCT00537602 ↗ | Miglustat / OGT 918 in the Treatment of Cystic Fibrosis | Terminated | Actelion | Phase 2 | 2007-11-01 | Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR). The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MIGLUSTAT
Condition Name
Clinical Trial Locations for MIGLUSTAT
Trials by Country
Clinical Trial Progress for MIGLUSTAT
Clinical Trial Phase
Clinical Trial Sponsors for MIGLUSTAT
Sponsor Name
